Shincort

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Shincort

For a quick summary of the medication, please see the table below.

Property Description
Active Ingredient Prednisone
Form Oral Tablet or Solution
Pharmacological Class Glucocorticoid (Corticosteroid)
Common Use Reducing inflammation and suppressing immune response
Essential Status Listed on the WHO Model List of Essential Medicines

Shincort is a trade name for the prescription-only medication prednisone, an established drug classified as a glucocorticoid, a type of corticosteroid. These compounds are synthetic versions of naturally produced adrenal hormones, primarily intended to manage inflammatory processes and immune responses in the body.

Prednisone is scientifically defined as a prodrug because it is inactive when consumed. It must first be processed by the liver, where it is converted into its active and potent form, prednisolone. This conversion is critical for the drug to deliver its therapeutic effects.

Its primary clinical function is to act as a powerful anti-inflammatory and immunosuppressive agent. This mechanism allows it to reduce swelling, pain, and redness, making it a critical treatment for a wide variety of conditions, including rheumatoid arthritis, severe allergic reactions, and certain autoimmune disorders. Due to its broad importance in treating acute and chronic conditions, prednisone is included on the World Health Organization’s Model List of Essential Medicines.

Regulatory References

  1. WHO Essential Medicines List for Prednisone
  2. FDA label information for Prednisone

What side effects are possible with Shincort?

Possible Side Effects and Safety Information

Shincort is a potent corticosteroid, and its safety profile is largely defined by the potential for systemic effects, which are generally dependent on the dose and duration of exposure.

Serious and Clinically Significant Adverse Reactions

Reported serious reactions include anaphylaxis (a life-threatening allergic reaction), Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, and Cushing syndrome. HPA axis suppression can lead to secondary adrenocortical insufficiency, particularly upon abrupt discontinuation. Serious neurologic events, including spinal cord infarction and paralysis, have been reported and necessitate that the drug is not approved for epidural or intrathecal administration.

Common Adverse Reactions and Organ Systems

Adverse effects commonly involve multiple system-organ classes, including:

  • Metabolic/Endocrine: Weight gain, fluid retention, hyperglycemia (increased blood sugar, potentially worsening diabetes), and changes in fat distribution.
  • Musculoskeletal: Osteoporosis (bone thinning) and muscle weakness.
  • Psychiatric/Nervous System: Mood swings, insomnia, anxiety, and depression.
  • Infections: Increased susceptibility to, and potential exacerbation of, existing or latent infections (e.g., fungal, bacterial, viral). Corticosteroids may also mask signs of infection.
  • Ophthalmic: Long-term use is associated with the development of posterior subcapsular cataracts and glaucoma (increased intraocular pressure).

Population-Specific Safety Considerations

Caution is advised in pediatric patients due to the potential for growth rate reduction. Due to the presence of benzyl alcohol in some formulations, particular care must be taken in neonates and premature infants, as this preservative has been associated with severe toxicity. Individuals with pre-existing conditions like hypertension, diabetes, or active infections require careful monitoring, as Shincort may worsen these conditions.

Overdose and Emergency Response

The official regulatory documents state that an acute overdose of Shincort (prednisone) is not generally expected to produce a severe or life-threatening clinical presentation. Despite this classification, the mandatory action for any suspected overexposure is to seek immediate medical attention. Emergency services, such as calling 911, must be contacted immediately if severe, life-threatening signs occur, including collapse, seizure, trouble breathing, or if the individual cannot be awakened, as required by governmental guidance.

The official overdose profile heavily emphasizes the risks associated with chronic overdosage or prolonged high-dose administration. These risks are formally documented and include manifestations of the Cushingoid state, fluid and sodium retention, hypertension, and electrolyte imbalances such as hypokalemia. Severe neurological and psychiatric disturbances, including convulsions, mood changes, and frank psychotic manifestations, are also documented outcomes linked to sustained high steroid levels. Treatment is strictly symptomatic and supportive, as no specific pharmaceutical antidote is documented in the prescribing information. Management for chronic overdosage, as described by regulators, involves dose reduction. Additionally, the growth and development of children on prolonged therapy must be carefully observed.

Therapeutic Uses of Shincort

Quick Facts: Shincort

  • Chronic Conditions: Helps address inflammation related to certain long-term diseases, including various forms of arthritis.
  • Dermatology: Used to manage inflammatory and pruritic symptoms of steroid-responsive skin conditions such as eczema and psoriasis.
  • Exacerbations: May be used as adjunctive therapy for short-term administration during acute episodes or flares of certain rheumatic disorders.

Shincort (Triamcinolone Acetonide) is an established therapeutic option used to manage inflammation in several body systems. It is primarily indicated as an anti-inflammatory agent. This product may be administered for the short-term relief of flare-ups associated with certain rheumatic disorders, including acute gouty arthritis and acute bursitis.

In dermatology, Shincort is utilized to address the inflammatory and itching symptoms of steroid-responsive dermatoses. This includes conditions such as various forms of dermatitis, lichen planus, and psoriasis. Additionally, the medication is employed in the management of specific allergic states that are unresponsive to conventional treatment, such as severe, incapacitating seasonal or perennial allergic rhinitis.

The pharmacological action is centered on reducing inflammation and certain immune system responses across a wide range of conditions. For a detailed list of approved uses and administration guidelines, patients should consult the official prescribing information.

Eligibility and Restrictions for Use

The eligibility profile for Shincort (Prednisone) is determined by official regulatory documents that define specific contraindications and conditional use requirements.

The medicine is contraindicated and must not be used by patients with a Systemic Fungal Infection or a known hypersensitivity to any component of the drug. Use is also prohibited in cases of Cerebral Malaria and Active Ocular Herpes Simplex due to the risk of severe complications.

While use is established for both Adults and Pediatric Populations, regulatory labels advise that long-term use in children is not recommended as it may be associated with growth suppression. Furthermore, patients receiving immunosuppressive doses must not receive Live or Live Attenuated Vaccines.

Conditional use and close monitoring are mandated for patients with certain pre-existing conditions. These include Hepatic Impairment, Renal Insufficiency, Diabetes Mellitus, Hypertension, Glaucoma, a history of Peptic Ulceration, and latent infections like Tuberculosis. Use during the first trimester of pregnancy is associated with potential fetal harm, and the active metabolite is excreted into human milk during lactation, requiring caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

  • Medicinal product categories with documented interactions: Cytochrome P450 3A4 (CYP3A4) Enzyme Inducers and Inhibitors, Antidiabetic Agents, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Potassium-Depleting Agents, and Anticholinesterase Agents.
  • Specific interacting medicines (if explicitly listed): Rifampin, Phenytoin, Ketoconazole, Itraconazole, Mifepristone, Metyrapone, and Fluoroquinolones.
  • Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interactions involving the CYP3A4 enzyme system leading to altered clearance; pharmacodynamic interactions leading to additive or synergistic risks.
  • Timing-based interaction rules (if applicable): Anticholinesterase agents should be withdrawn at least 24 hours prior to initiating corticosteroid therapy, if possible.
  • Population-specific interaction notes (if applicable): The increased risk of tendon rupture when co-administered with Fluoroquinolones is explicitly noted to be particularly significant in the elderly population.
  • Interaction-related restrictions: Administration of Live Attenuated Vaccines/Toxoids is restricted during periods of high-dose immunosuppressive corticosteroid therapy.

Interaction classifications (high-level)

  • Interaction severity classification (as defined in official documents): Contraindicated or Not Recommended combinations; Interactions requiring Dosage Adjustment or Monitoring; Interactions resulting in Additive Toxicity.
  • Regulatory basis (EMA / FDA / etc.): FDA / NIH (DailyMed), Medsafe.

Resulting interaction structure

  • Official interaction statements: Co-administration with CYP3A4 inhibitors (e.g., Ketoconazole) may result in increased plasma concentrations, while inducers (e.g., Rifampin) may cause decreased plasma concentrations. The combination with NSAIDs is documented to increase the risk of gastrointestinal ulceration, and combination with Potassium-Depleting Agents increases the risk of hypokalemia. Mifepristone and Metyrapone are formally listed as combinations that are not recommended. Herbal products such as St. John’s Wort are cited as CYP3A4 inducers.

  • Connection to the overall interaction profile (2–4 sentences): The regulatory documents define the interaction structure by identifying substances that alter systemic exposure via the CYP3A4 metabolic pathway and those that create additive pharmacodynamic risks, such as electrolyte imbalance or GI toxicity. These official statements delineate specific drug-drug combinations that are either restricted, contraindicated, or require proactive monitoring and potential adjustment of the co-administered therapy.

Mechanism of Action

The action of Shincort (Prednisone), via its active form Prednisolone, is based on manipulating genetic instructions within the cell nucleus to modulate inflammatory and immune processes.

Genomic Reprogramming of Inflammatory Signaling

The drug functions as an agonist at the universally expressed Glucocorticoid Receptor (GR), forming a complex that moves to the cell nucleus. This complex engages in transrepression, which switches off genes for pro-inflammatory mediators like NF-kappa B, and transactivation, which activates genes for anti-inflammatory proteins. This system-wide genomic control initiates the mechanism that leads to the modulation of the inflammatory response.

Upstream Interruption of Eicosanoid Cascades

The genomic action rapidly induces the synthesis of the protein Lipocortin-1, which is an inhibitor of the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the drug mechanism prevents the formation of arachidonic acid, the necessary precursor for synthesizing signaling molecules like prostaglandins and leukotrienes. This upstream interruption provides a critical** control point for reducing the biological component of inflammation.

Modulating Immune Cell Traffic and Metabolism

The mechanism modulates key functions of circulating immune cells, promoting the redistribution of lymphocytes, monocytes, and eosinophils out of the bloodstream and accelerating their clearance. Simultaneously, the GR activation also engages linked metabolic pathways, driving processes like gluconeogenesis (glucose production) as an unavoidable consequence of its native role in metabolic homeostasis.

Dosage and Administration Information

The usage of Shincort is defined by official protocols that govern its oral administration and dosing structure. The medicine is available as an oral tablet and a solution.

Administration begins with an initial daily dose ranging from 5 mg to 60 mg, which is then gradually reduced to the lowest effective maintenance dose. This reduction process, known as titration, is used to correctly manage the condition over time.

For daily regimens, the medication is often administered as a single morning dose to harmonize with the body's natural hormone cycle. The dose should be taken with food or milk to reduce the risk of stomach irritation. When using liquid forms, a calibrated measuring device must be used to ensure dosing accuracy.

Use over time is categorized as either short-term therapy for acute flare-ups or long-term maintenance. After any extended course, Shincort must never be stopped abruptly. Protocols mandate a gradual withdrawal (tapering) using progressively smaller doses to prevent the development of acute adrenal insufficiency. Specific formulations, such as delayed-release tablets, must be swallowed whole and cannot be crushed or broken. Pediatric dosing is based on the disease's severity and patient response, not solely on size or age.

Recent Clinical Evidence

Research evidence / Overview of studies for Shincort (Prednisone)


Evidence for Chronic Inflammatory Conditions (e.g., Rheumatoid Arthritis)

The research base primarily relies on Randomized Controlled Trials (RCTs) and systematic reviews in adults with active RA, often alongside other long-term therapies. Studies explored how structural changes in joints and patient-reported outcomes like morning stiffness and daily functioning were measured over intermediate and long-term intervals. Findings describe patterns related to measured changes in joint progression.


Evidence for Acute Disease Flare-Ups

Short-term clinical trials have examined the medicine’s use during sudden, episodic flare-ups, such as acute gouty arthritis. These studies monitored outcomes related to inflammatory states, focusing on changes measured in pain and local swelling over very short treatment periods (5–14 days). Research provides insight into short-term changes, but the evidence is limited regarding subsequent recurrence after treatment ends.


Evidence for Dermatologic and Allergic Conditions

Studies, including controlled trials and challenge studies, explored the medicine for severe allergic states or steroid-responsive skin conditions like eczema. Outcomes measured included changes in skin inflammation and perceived discomfort (itching). Evidence quality varies across studies, and the data for achieving stable, long-term remission in chronic skin conditions is often insufficient in large-scale RCTs.


Long-Term Evidence and Research Gaps

The research base includes studies observing responses over defined time intervals to understand the durability of effects. However, long-term outcomes are not fully established for all aspects of the medicine’s use. Evidence remains limited for the use of very low daily doses (e.g., less than 5 mg) against placebo, and research specifically dedicated to certain special populations like children and older adults with multiple comorbidities remains insufficient, with findings primarily applying to the adult populations studied.

Key Studies & References

  1. Systematic Review of Low-Dose Glucocorticoids in Rheumatoid Arthritis: Efficacy and Structural Outcomes
  2. American College of Rheumatology (ACR) Guideline on Glucocorticoid Management and Dose Limitations

Frequently Asked Questions (FAQ)

Common questions about Shincort (FAQ)


Q: Is Shincort the same kind of drug as prednisone or hydrocortisone?

Shincort is a trade name for the drug prednisone. Both prednisone and hydrocortisone belong to the corticosteroid class of medications. Official sources describe prednisone as an intermediate-acting glucocorticoid, unlike the short-acting hydrocortisone.


Q: What is the main difference between Shincort and other steroid medications?

Shincort (prednisone) is classified primarily as a glucocorticoid. This means its activity is mainly focused on suppressing the immune system and reducing inflammation. Regulatory documents note that it has relatively low mineralocorticoid activity compared to some other steroids, and this classification aligns with its primary use for conditions where anti-inflammatory action is targeted.


Q: How quickly does Shincort start working after taking it?

Shincort must first be converted by the liver into its active form, prednisolone. This active substance is rapidly absorbed after being taken by mouth. According to regulatory documentation, peak concentrations of the active drug in the blood typically occur within 1 to 3 hours of administration.


Q: How long do the effects of Shincort last in the body?

The active ingredient is cleared from the bloodstream with a half-life of roughly 2 to 4 hours. However, the biological effects of the drug on the body last significantly longer. The longer biological effect is a factor that supports its use in certain once-daily treatment regimens.


Q: Is it normal to feel tired or dizzy when starting Shincort?

Official product information lists several common adverse effects involving the central nervous system, such as insomnia, anxiety, and mood changes. While tiredness and dizziness are not listed on all primary labels as a common reaction, their occurrence may be related to these broader systemic effects.


Q: What common foods or drinks might interact with Shincort?

The official instructions for use state that Shincort should be taken with food or milk to help reduce potential irritation to the stomach. Furthermore, as the drug can affect metabolic processes, regulatory guidance indicates caution regarding substances, such as foods high in salt or sugar, that might contribute to fluid retention or elevated blood glucose levels.


Q: Can I drink coffee while I am taking Shincort?

While the primary regulatory labels do not prohibit the use of coffee, some official patient handouts advise caution regarding the intake of large amounts of caffeinated beverages, including coffee, tea, and soda. This is due to the potential for central nervous system stimulation and related effects like anxiety or insomnia.


Q: What is the risk of developing dependence on Shincort?

Use of the medicine, especially long-term, can cause suppression of the HPA axis, which is a normal function of the body's hormone production. This is known as physiological dependence (it is not addiction). Official protocol describes the requirement for gradual withdrawal (tapering) to reduce the risk of a severe complication called acute adrenal insufficiency.


Q: Does Shincort interact with common pain relievers like ibuprofen or acetaminophen?

Regulatory documents explicitly state that combining Shincort with NSAIDs (a class including ibuprofen) increases the risk of gastrointestinal ulceration and bleeding. In contrast, acetaminophen is not typically listed in mandatory interaction warnings as requiring a dosage adjustment or special restriction.


Q: Are there any generic versions of Shincort available?

Yes. Shincort is simply a trade name used for the medicine prednisone. Prednisone is a long-established and widely used drug that is available in numerous generic formulations.


Q: Can Shincort be taken with herbal supplements or vitamins?

Certain herbal products, such as St. John’s Wort, are listed in regulatory documents because they can interact with the drug’s metabolism and decrease its effectiveness. Official warnings state that information regarding the use of all herbal supplements, vitamins, and over-the-counter products should be discussed with a healthcare provider.


Q: What is the difference between a systemic side effect and a local side effect of Shincort?

As an oral medication, Shincort is absorbed into the entire body, causing systemic effects that can impact multiple organ systems, such as bone density and metabolism. The official label explicitly restricts the use of the drug for local administration (such as injections into the spinal fluid) due to the risk of severe neurologic adverse events.


Q: What is the primary mechanism that causes the side effects of Shincort?

The side effects stem directly from the drug's core action of activating the Glucocorticoid Receptor (GR) in cells across the entire body. This single mechanism drives both the desired immune suppression and the resulting changes in metabolism and hormone balance, such as gluconeogenesis (the production of glucose in the body).


Q: Does Shincort cause thinning of the skin?

Yes, regulatory documents list thinning of the skin (atrophy) as a potential adverse effect associated with oral corticosteroid use. Other related skin effects that may be experienced include easy bruising and a slower rate of wound healing.


Q: Is it necessary to carry an ID card when taking Shincort?

Patients receiving long-term treatment with systemic glucocorticoids may be recommended by regulatory guidance to carry an alert card or wear a medical ID bracelet. This is because the drug's potential to cause adrenal suppression could require special attention or altered emergency treatment protocols from medical staff.


Q: Does Shincort affect how my body heals from cuts or injuries?

Yes, official documents list slower wound healing as a possible adverse reaction to oral corticosteroids. This effect is described as related to the drug’s immunosuppressive action, which can slow the body's natural inflammatory and repair responses.


Q: Do any official documents state that Shincort is a controlled substance?

No. Regulatory bodies categorize Shincort (prednisone) as a prescription-only medication. It is not classified as a controlled substance under government acts, meaning it does not fall into the scheduled categories (Schedule I-V) that cover drugs with a high risk of abuse.


Q: What is the purpose of the 'Warnings and Precautions' section in Shincort's official documentation?

The Warnings and Precautions section is a mandated part of official drug documentation designed to flag situations requiring extra care. It details the potential risks of the drug, such as HPA axis suppression, and specifies pre-existing conditions (like diabetes or hypertension) that require close monitoring or adjustment to the treatment plan.

How should Shincort be stored and disposed of?

Storage and Disposal of Shincort (Prednisone)

Official regulatory documents define specific requirements for storing and disposing of Shincort (prednisone) oral formulations to maintain stability and ensure safety.


Storage Conditions

Shincort must be stored at Controlled Room Temperature, which is 20^circ to 25^circC (68^circ to 77^circF). The medication must be kept in its original container with the lid tightly closed to protect it from moisture. Storage in high-humidity areas, such as a bathroom, is prohibited. For safety, the product must be stored securely and kept out of the reach of children.


Disposal Instructions

Unused or expired Shincort should be disposed of using a drug take-back program when available. If a take-back program is unavailable, the medicine should be mixed with an unpalatable material (like dirt or coffee grounds), sealed in a plastic bag, and placed in the household trash. The product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Shincort found in:

A-Z Index: